Guggenheim Capital LLC Intercept Pharmaceuticals, Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$9.99 - $18.71 $222,627 - $416,952	22,285 New	22,285 $413,000
Q4 2020 Feb 16, 2021	SELL	$24.48 - $42.47 $865,539 - $1.5 Million	-35,357 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$39.09 - $53.44 $55,038 - $75,243	1,408 Added 4.15%	35,357 $1.47 Million
Q2 2020 Aug 14, 2020	BUY	$46.7 - $92.04 $514,447 - $1.01 Million	11,016 Added 48.04%	33,949 $1.63 Million
Q1 2020 Jun 02, 2020	SELL	$48.35 - $118.68 $243,877 - $598,621	-5,044 Reduced 18.03%	22,933 $1.44 Million
Q4 2019 Feb 14, 2020	SELL	$57.36 - $124.1 $159,747 - $345,618	-2,785 Reduced 9.05%	27,977 $3.47 Million
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $9,801 - $13,436	-167 Reduced 0.54%	30,762 $2.04 Million
Q2 2019 Aug 14, 2019	BUY	$77.77 - $120.68 $185,014 - $287,097	2,379 Added 8.33%	30,929 $2.46 Million
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $72,270 - $94,975	787 Added 2.83%	28,550 $3.19 Million
Q4 2018 Feb 14, 2019	SELL	$85.79 - $126.46 $204,437 - $301,354	-2,383 Reduced 7.9%	27,763 $2.8 Million
Q3 2018 Nov 14, 2018	SELL	$88.49 - $127.55 $546,956 - $788,386	-6,181 Reduced 17.01%	30,146 $3.81 Million
Q2 2018 Aug 14, 2018	BUY	$60.0 - $85.67 $1.43 Million - $2.04 Million	23,766 Added 189.2%	36,327 $3.05 Million
Q1 2018 May 15, 2018	SELL	$52.72 - $67.25 $1.28 Million - $1.64 Million	-24,350 Reduced 65.97%	12,561 $772,000
Q4 2017 Feb 14, 2018	SELL	$58.2 - $72.76 $540,096 - $675,212	-9,280 Reduced 20.09%	36,911 $2.16 Million
Q3 2017 Nov 14, 2017	BUY	$57.01 - $118.75 $2.63 Million - $5.49 Million	46,191	46,191 $2.68 Million

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account